1 month Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates Zacks
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
X